Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer TherapyRecent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
- Other Titles
- Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
- Authors
- Ho-Jae Lee
- Issue Date
- Dec-2020
- Publisher
- 대한암예방학회
- Keywords
- TGF-b; Tumor microenvironment; Tumor escape; Antineoplastic agents; Immune checkpoint inhibitors
- Citation
- 대한암예방학회지, v.25, no.4, pp.213 - 222
- Journal Title
- 대한암예방학회지
- Volume
- 25
- Number
- 4
- Start Page
- 213
- End Page
- 222
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79552
- ISSN
- 2288-3649
- Abstract
- TGF-β is a multifunctional cytokine that plays an important role in both physiologic and pathologic processes, including cancer.
Importantly, TGF-β has a dual role in tumorigenesis, acting as a tumor suppressor or a tumor promoter, depending on the stage of tumor development. The aberrantly upregulated production of TGF-β has been strongly implicated in tumor progression, angiogenesis, and metastasis, as well as immune evasion. Therefore, hyperactivated TGF-β signaling is considered a potential therapeutic target for cancer therapy. Numerous inhibitors of overactivated TGF-β signaling have been developed, and some of them are currently in clinical trials. This review focuses on the TGF-β signaling that contributes to tumor progression and immune evasion in the tumor microenvironment and presents recent achievements on TGF-β signaling inhibition as a single or combined therapeutic approach in cancer therapy.
Key Words TGF-b, Tumor microenvironment, Tumor escape, Antineoplastic agents, Immune checkpoint inhibitors
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79552)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.